Association Between EGFR and ALK Mutation Status on Patient-Reported Symptoms After Palliative Radiation for Bone Pain in NSCLC

Sit, Daegan; Bale, Michelle; Lapointe, Vincent; Olson, Robert; Hsu, Fred

doi:10.1016/j.jtocrr.2022.100371

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genetic links that involved EGFR and pain were also found in other painful disease conditions. Recently, it was demonstrated that there was a positive association between tumors with EGFR mutations and higher rates of pain in response to palliative radiotherapy in an analysis of NSCLC patient-reported outcomes [71], further supporting the involvement of EGFR in both cancer progression and pain signaling. In an interactome study aimed to identify ligand-receptor pathways relevant to pain in a cell type-specific manner, Dr. Price's group created interactome maps between human DRG sensory neurons and rheumatoid arthritis-associated synovial macrophages and pancreatic tumor tissue using published RNA-seq datasets.…”

Section: Clinical Studies and Genetic Associationsmentioning

confidence: 90%

Repurposing EGFR Inhibitors for Oral Cancer Pain and Opioid Tolerance

Santi,

Zhang,

Liu

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Oral cancer pain remains a significant public health concern. Despite the development of improved treatments, pain continues to be a debilitating clinical feature of the disease, leading to reduced oral mobility and diminished quality of life. Opioids are the gold standard treatment for moderate-to-severe oral cancer pain; however, chronic opioid administration leads to hyperalgesia, tolerance, and dependence. The aim of this review is to present accumulating evidence that epidermal growth factor receptor (EGFR) signaling, often dysregulated in cancer, is also an emerging signaling pathway critically involved in pain and opioid tolerance. We presented preclinical and clinical data to demonstrate how repurposing EGFR inhibitors typically used for cancer treatment could be an effective pharmacological strategy to treat oral cancer pain and to prevent or delay the development of opioid tolerance. We also propose that EGFR interaction with the µ-opioid receptor and glutamate N-methyl-D-aspartate receptor could be two novel downstream mechanisms contributing to pain and morphine tolerance. Most data presented here support that repurposing EGFR inhibitors as non-opioid analgesics in oral cancer pain is promising and warrants further research.

show abstract

Section: Clinical Studies and Genetic Associationsmentioning

confidence: 90%